Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-10-07

Recursion Pharmaceuticals, Inc.

Recursion is a clinical-stage biotech that uses proprietary biological data, automated labs, and AI-driven discovery workflows to build internal drug programs and pharma collaborations.

ai automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform Proof Could Unlock a 2-5x Path

This is still a proof-conversion story, not a software story. If proprietary data and automated discovery translate into approval-grade evidence, better partner economics, and one owned commercial asset, the equity can rerate meaningfully; if not, it risks staying a volatile discovery vendor.

Analysis

Thesis

Recursion is a leveraged bet that falling AI and automation costs make its proprietary biology-data loop more valuable, but the stock only rerates hard if that loop converts into approval-grade proof, milestone-heavy partnerships, and at least one owned asset with real commercial or out-license economics by 2031.

Last Economy Alignment

Recursion benefits as cognition gets cheaper because it owns proprietary biology data, automated lab throughput, and a closed discovery loop rather than a thin software wrapper. Value capture is still gated by clinical and regulatory proof, so it is strongly helped by the Last Economy but is not itself the core bottleneck being monetized.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.7x (from 5 most recent analyses)

Reasoning

The upside path is a business-model upgrade, not just more experiments. If revenue mix shifts from lumpy collaboration revenue toward owned assets, milestone streams, royalties, and selective model licensing, the market can value Recursion more like a validated platform-biotech than a speculative discovery vendor. I keep the case in 2-5x territory because proof still depends heavily on one lead rare-disease asset and a small number of partner conversions.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The core risk is proof conversion, not AI output volume. Recursion has enough technical credibility to matter, but it still must prove that proprietary data and automated discovery can repeatedly create approval-oriented assets before cash runway and partner bargaining power become binding. If REC-4881 gains a workable path and one more internal or partnered program validates the engine, risk drops fast; if not, the business can stay trapped as a cash-burning discovery platform.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new company-level operating release appeared in the last 7-10 days, so the thesis still centers on the November 2, 2026 REC-4881 plenary data update and the expected late-2026 FDA-path update.
October 2, 2026 SEC filings were Form 4 insider reports rather than operating disclosures, so they do not materially change the growth case.
The stock moved sharply in early October without a matching new fundamental filing, which looks more like catalyst positioning ahead of November than a new information regime.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.42

They control proprietary biology data, automated labs, and a discovery workflow that should get more valuable as AI makes design and experimentation faster. The risk is that regulators, not models, still set the pace, and large pharma can keep the best economics in-house unless clinical proof becomes repeatable.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.22

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research